血栓管理设备的全球市场:洞察，竞争情形，市场预测:2032年

2024年，血栓管理设备市场规模达18.3879亿美元。预计2025年至2032年期间，该市场规模将以4.63%的复合年增长率成长，到2032年将达到26.3273亿美元。心血管疾病、糖尿病和高血压等生活方式相关疾病的盛行率不断上升，以及持续的产品创新，正在推动血栓管理设备市场的成长。心血管疾病及其相关风险正在推动对先进血栓预防和治疗技术的需求。此外，微创高效设备（例如机械血栓切除工具和导管系统）的新技术发展，正在推动市场发展，并使医护人员更轻鬆地管理血栓疾病。预计这些综合因素将在2025年至2032年的预测期内推动血栓管理设备市场整体扩张。

血栓管理设备市场动态：

根据英国心臟基金会提供的最新数据（2024年），全球约有6.2亿人（约占全球人口的1/13），患有心臟和循环系统疾病。此外，根据英国心臟基金会提供的最新数据（2024年），冠状动脉（缺血性）心臟病影响全球约2亿人，其中包括约1.1亿名男性和8,000万名女性。此外，约有5600万女性和4500万男性是卒中倖存者。据估计，全球至少有1,300万人患有先天性心臟病，另有数百万人可能未被诊断。

心血管疾病（CVD），包括心臟病发作、中风和周边动脉疾病，发病率的不断上升，大大推动了血栓管理设备市场的发展。这些疾病通常伴随血栓形成，如果不及时治疗，可能导致危及生命的併发症。血栓管理设备，包括机械血栓切除系统和导管介入血栓溶解术，为去除或溶解血栓提供了微创选择，改善了患者的预后，并减少了对复杂手术的需求，从而推动了全球市场的成长。

此外，根据国际糖尿病联盟 (IDF) 最新数据，2021 年约有 5.37 亿 20 至 79 岁的成年人患有糖尿病。预计到 2030 年，这一数字将增至 6.43 亿，到 2045 年将增至 7.83 亿。

此外，根据 IDF 糖尿病地图集提供的最新数据，2022 年全球 875 万第 1 型糖尿病患者中，有 152 万人未满 20 岁。此外，2022 年新发生 1 型糖尿病患者中 62% 年龄在 20 岁或以上。糖尿病盛行率的上升推动了对血栓管理设备的需求，因为糖尿病会显着增加血管併发症（包括血栓形成）的风险。这种风险的增加需要先进的血栓管理解决方案，例如血栓切除装置、导管介导的血栓溶解术以及其他旨在快速溶解或清除血栓、改善血流并减少併发症的微创手术，从而促进全球血栓管理设备市场的整体成长。

此外，各公司正透过扩大血栓管理设备的生产规模和获得新产品的批准，策略性地扩大其市场占有率，从而推动进一步的成长。例如，2025年3月，Imperative Care, Inc.宣布其82公分Symphony™ 16F导管已获得美国食品药物管理局(FDA) 510(k)批准。该导管是该公司最新的创新产品，旨在改善静脉血栓形成患者的照护。静脉血栓形成是一种由腿部和腹部静脉中形成的血栓引起的严重且危及生命的疾病。

然而，产品召回事件的增加以及血栓管理器械相关併发症的风险，例如出血、血管损伤和感染，可能会阻碍血栓管理器械市场的未来发展。

血栓管理器械市场区隔分析：

按产品类型划分的血栓管理市场中，支架取栓器预计将在2024年占据最大占有率。这可能是由于使用支架取栓器进行机械血栓切除术的优势，据报道，与单纯药物治疗相比，支架取栓器在急性中风患者中可带来更佳的临床疗效。此外，支架取栓器的安全性与全身性溶栓疗法相似。这些器械旨在以机械方式从脑部阻塞的动脉中清除血栓，从而在关键时间内快速有效地恢復血流，防止长期神经损伤。

此外，产品设计的改进，例如加入铂金以提高可见度（Trevo Provue 和 Solitaire Platinum）以及将长度延长至 40 毫米，有助于改善首次再灌注结果。可回收自膨胀式血栓切除装置的出现提供了更多优势，例如可立即恢復血流，无需放置永久性支架，从而降低支架内再狭窄的可能性。与单纯的传统溶栓疗法相比，支架回收器可提供更佳的疗效，包括更高的血管再通率、更好的功能恢復和更低的死亡率。这使得它们被纳入主要的卒中治疗指南，并在世界各地的医院和卒中中心加速推广。此外，技术创新，例如具有增强径向力、改善血栓完整性和改进导航的下一代支架回收器，正在进一步扩展支架回收器的临床应用。

此外，新产品的推出可能会在预测期内推动全球支架取栓器市场蓬勃发展。例如，2024年8月，Gravity Medical Technology宣布推出其下一代中风治疗设备－中子抽吸导管和Supernova支架取栓器。 Supernova支架取栓器的创新设计增强了对富含纤维蛋白的硬性（白色）血块的捕获和清除能力，而这类血块在非白种人群中更为常见。

因此，基于上述因素，预计在预测期内，支架取栓器类别将创造可观的收入，并推动全球血栓管理设备市场的整体成长。

预计到2024年，北美将在血栓管理设备市场中占据所有地区中的最高占有率。由于肥胖、高血压和糖尿病盛行率上升，深部静脉栓塞 (DVT) 和栓塞盛行率上升，人口老化，癌症盛行率上升以及政府在疾病治疗意识方面的举措不断增多，预计北美血栓管理设备市场在预测期内将出现正增长。

根据美国疾病管制与预防中心 (CDC) 2024 年的最新数据，2022 年约有 4.9% 的成年人被诊断出患有冠心病。此外，预计到 2023 年，美国将有 1,210 万人罹患心房颤动。此外，美国每年有超过 79.5 万人罹患中风，其中约 61 万人是首次中风。值得注意的是，其中近18.5万例中风患者（约占四分之一）曾经中风。

冠状动脉心臟病 (CHD) 盛行率的上升极大地推动了血栓管理设备市场的发展。由于血栓通常在冠状动脉中形成，因此对恢復血流和预防心臟病发作的有效治疗的需求日益增长。血栓切除设备和栓塞系统等血栓管理设备对于管理这种疾病至关重要，并正在推动其在医院和急诊室的应用。

此外，根据美国疾病管制与预防中心 (CDC) 提供的最新报告（2024 年），估计各年龄层将有 3,840 万人（占美国人口的 11.6%）患有糖尿病。此外，18 岁及以上人口中约有 3,810 万人患有糖尿病，占美国成年人口的 14.7%。糖尿病常导致周边动脉疾病和深部静脉血栓等併发症，这些併发症会导致血栓阻塞血管，阻碍血液循环。糖尿病患者对有效血栓预防和治疗的需求日益增长，这推动了血栓管理设备（包括血栓切除术和导管系统）在医院和门诊的普及，扩大了该地区的市场。

此外，美国人口癌症盛行率的上升也是积极影响美国血栓管理设备市场成长的关键因素之一。根据 GLOBOCAN 提供的最新数据，2022 年北美新增癌症病例估计为 267 万例，预计到 2045 年将增加至 383 万例。癌症患者被认为存在某些异常的凝血因子，这会增加血栓形成的可能性。此外，化疗也会增加静脉血栓的风险，导致深部静脉血栓形成。因此，预计美国癌症盛行率的上升将推动血栓管理设备需求的成长，增加产品需求，并支持北美血栓管理设备市场的成长。

此外，主要市场参与者的策略活动增加，可能会在预测期内迅速推动该地区血栓管理设备市场的发展。例如，2023年6月，全球医疗保健公司Penumbra, Inc.获得FDA批准，并推出了先进的动脉血栓清除系统Lightning Bolt™ 7。本设备结合Lightning智慧抽吸技术与微处理器演算法，实现了可调节的吸力。该设备旨在快速清除较大的纤维性动脉血栓，同时最大限度地减少出血，适用于急性肢体缺血(ALI)、休眠血栓和内臟阻塞等病症。

因此，预计上述因素将在预测期内推动北美血栓管理设备市场的成长。

血栓管理设备市场的主要参与者

血栓管理设备市场的主要参与者包括爱德华生命科学公司 (Edward LifeSciences Corporation)、史赛克 (Stryker)、医疗器材业务服务公司 (Medical Device Business Services, Inc.)、美敦力公司 (Medtronic PLC)、Penumbra、Microvention 公司、泰尔茂公司 (Terumo Corporation、波士顿科学公司 (Yusston Sci)、Yuscan妈妈、Hashcan、Hflowa)、波士顿科学公司 (Cston00)、Hillas G Ltd.、荷兰皇家飞利浦公司 (Koninklijke Philips N.V.)、phenox GmbH、AngioDynamics、ARGON MEDICAL、BD、B. Braun Melsungen AG、康德乐 (Cardinal Health)、Braille Biomedica 和库克 (Cook)。

血栓管理设备市场的最新发展：

• 2024年4月，Penumbra Inc. 推出了 Lightning Flash 2.0——用于快速清除血栓的最新 CAVT 技术。
• 2024年2月，强生医疗科技公司 CERENOVUS, Inc. 宣布推出 CEREGLIDE™ 71 中间导管，专为急性缺血性中风患者的血管重建而设计。这款新一代导管属于 CEREGLIDE 系列，经过优化，可直接将支架回收器（例如 EMBOTRAP™ III 血管重建装置）吸入并输送至神经血管系统。

血栓管理设备市场报告重点

• 目前血栓管理设备市场规模分析（2024 年）及 8 年市场预测（2025-2032 年）
• 过去三年主要产品/技术发展、併购、合作及合资企业
• 主导血栓管理设备市场的主要公司
• 血栓管理设备市场中竞争对手面临的各种机会
• 2024 年的主要细分市场及其 2032 年的表现
• 目前血栓管理设备市场中表现最佳的地区和国家
• 企业应重点关注的血栓管理设备市场成长机会的地区和国家

经常血栓管理设备市场常见问题

1. 血栓管理设备

• 血栓管理设备是用于清除週边血管和神经血管中血栓的医疗器械。

2. 血栓管理设备市场

• 预计2024年血栓管理设备市场规模将达到18.3879亿美元，2025年至2032年的复合年增长率为4.63%，到2032年将达到26.3273亿美元。

3.血栓管理设备市场的驱动因素

• 心血管疾病、糖尿病和高血压等生活方式相关疾病的盛行率不断上升，以及持续的产品创新，正在推动血栓管理设备市场的成长。心血管疾病及其相关风险正在推动对先进血栓预防和治疗技术的需求。此外，微创高效设备（例如机械血栓切除工具和导管系统）的新发展正在推动市场发展，并使医护人员更轻鬆地进行血栓管理。预计这些综合因素将在2025年至2032年的预测期内推动整个血栓管理设备市场的成长。

  4.血栓管理设备市场的主要参与者

  • 血栓管理设备市场的主要参与者包括：爱德华生命科学公司 (Edward LifeSciences Corporation)、史赛克 (Stryker)、医疗器材业务服务公司 (Medical Device Business Services, Inc.)、美敦力公司 (Medtronic PLC)、Penumbra、Microvention 公司、泰尔茂公司 (Terumo Corporation Corporation、波士顿科学公司 (Boston)、Vston Perf）、Pflowas） Ltd.、荷兰皇家飞利浦公司 (Koninklijke Philips N.V.)、phenox GmbH、AngioDynamics、ARGON MEDICAL、BD、B. Braun Melsungen AG、康德乐 (Cardinal Health)、Braille Biomedica 和库克 (Cook)。

  5.血栓管理设备市场最大占有率地区

  • 预计到2024年，北美将在所有地区中占据血栓管理设备市场的最大占有率。由于一些关键成长因素的重要性，北美血栓管理设备市场预计将在预测期内实现正增长，这些因素包括肥胖、高血压和糖尿病患病率的上升，深部静脉血栓 (DVT) 和栓塞患病率的上升，人口老龄化，癌症患病率的上升，以及政府在疾病治疗意识方面的举措不断增多。

  目录

  第1章 血栓管理设备市场报告的简介

  第2章 血栓管理设备市场摘要整理

  第3章 竞争情形

  第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

  第5章 血栓管理设备市场主要原因分析

  • 血栓管理设备推动市场要素
    • 心血管疾病盛行率上升
    • 糖尿病和高血压等生活型态相关疾病发生率上升
    • 产品开发活动增加全球
  • 血栓管理设备市场限制与课题
    • 产品召回数量不断增加
    • 设备相关併发症风险
  • 血栓管理设备市场机遇
    • 人工智慧整合

  第6章 血栓管理设备市场:波特的五力分析

  第7章 血栓管理设备市场评估

  • 各产品类型
    • 血栓清除装置
    • 栓塞解剖导管
    • 下腔静脉滤器
    • 压缩服装类
    • 其他
  • 各终端用户
    • 医院
    • 门诊病人手术中心
    • 居家照护
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

  第8章 血栓管理设备市场企业与产品简介

  • Edward LifeSciences Corporation
  • Stryker
  • Medical Device Business Services, Inc.
  • Medtronic PLC
  • Penumbra
  • Microvention Inc.
  • Terumo Corporation
  • Boston Scientific Inc.
  • Abbott
  • Acandis GmbH
  • Perflow Medical Ltd.
  • Koninklijke Philips N.V.
  • phenox GmbH
  • AngioDynamics
  • ARGON MEDICAL
  • BD
  • B. Braun Melsungen AG
  • Cardinal Health
  • Braile Biomedica Cook

  第9章 KOL的见解

  第10章 计划方法

  第11章 关于DelveInsight

  第12章 免责声明和咨询方式

Clot Management Devices by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrievable and Permanent], Compression Garments, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of cardiovascular diseases, increasing prevalence of lifestyle disorders such as diabetes and hypertension, and increased in product developmental activities across the globe.

The clot management devices market was valued at USD 1,838.79 million in 2024, growing at a CAGR of 4.63% during the forecast period from 2025 to 2032 to reach USD 2,632.73 million by 2032. The rising prevalence of cardiovascular diseases, lifestyle disorders like diabetes and hypertension, and ongoing product innovation are driving the growth of the clot management devices market. Cardiovascular conditions and related risks from these disorders increase demand for advanced clot prevention and treatment technologies. Additionally, new developments in less invasive and more effective devices, such as mechanical thrombectomy tools and catheter-based systems, are boosting market expansion, making it easier for healthcare providers to manage blood clots. Together, these factors are expected to boost the overall market for clot management devices during the forecast period from 2025 to 2032.

Clot Management Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases. Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, affected an estimated 200 million people globally in which approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.

The rising incidence of cardiovascular diseases (CVDs), such as heart attacks, strokes, and peripheral artery disease, significantly boosts the market for clot management devices. These conditions are often associated with the formation of blood clots, which can lead to life-threatening complications if not treated promptly. Clot management devices, including mechanical thrombectomy systems and catheter-directed thrombolysis, provide minimally invasive options for removing or dissolving clots, improving patient outcomes and reducing the need for complex surgeries thereby escalating the market growth across the globe.

Additionally, according to the recent update provided by the International Diabetes Federation, in 2021, approximately 537 million adults aged 20-79 were living with diabetes. This number was projected to rise to 643 million by 2030 and 783 million by 2045.

Additionally, as per the recent data provided by the IDF Diabetes Atlas, in 2022, out of the 8.75 million people living with type 1 diabetes worldwide, 1.52 million were under 20 years old. Additionally, 62% of all new type 1 diabetes cases in 2022 occurred in people aged 20 years or older. The increasing prevalence of diabetes is driving the demand for clot management devices, as diabetes significantly raises the risk of vascular complications, including blood clot formation. This elevated risk necessitates advanced clot management solutions such as thrombectomy devices, catheter-directed thrombolysis, and other minimally invasive procedures designed to quickly dissolve or remove clots, improving blood flow and reducing complications and thereby boosting the overall market of clot management devices across the globe.

Additionally, companies are amplifying their production of clot management devices and gaining approvals for the new products, thereby strategically expanding their market presence and driving further growth. For instance, in March 2025, Imperative Care, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82cm version of its SymphonyTM 16F Catheter, the company's latest innovation designed to elevate care for patients with venous thrombosis, a serious condition caused by a blood clot forming in the veins of the legs or abdomen that can have a life-threatening impact if left untreated.

However, the increased number of product recalls and the risk of complications associated with clot management devices such as bleeding, vessel damage, or infection may hinder the future market of clot management devices.

Clot Management Devices Market Segment Analysis:

Clot Management Devices by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrievable and Permanent], Compression Garments, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the clot management market, the stent retrievers category is expected to hold the largest share in the year 2024. This can be ascribed to their advantages such as mechanical thrombectomy with stent retrievers is reported to produce superior clinical outcomes in acute stroke patients compared to medical therapy alone. In addition to that, stent retrievers have a safety profile similar to that of systemic thrombolytic therapy. These devices are designed to mechanically remove blood clots from blocked arteries in the brain, thereby restoring blood flow quickly and effectively often within the critical window for preventing long-term neurological damage.

Moreover, improvements in product design such as the incorporation of platinum for improved visibility (Trevo Provue and Solitaire Platinum) and longer lengths up to 40 mm have helped in improving the first-pass reperfusion outcomes. The entry of recoverable self-expanding thrombectomy devices further offers advantages such as the devices restore flow immediately and avoid the placement of a permanent stent, immediate restoration of blood, and eliminating the need for the placement of a permanent stent thereby reducing the chances of in-stent restenosis. Stent retrievers offer superior outcomes compared to traditional thrombolytic drug therapy alone, including higher rates of recanalization, improved functional recovery, and reduced mortality. This has led to their inclusion in major stroke treatment guidelines and accelerated adoption across hospitals and stroke centers globally. Furthermore, technological innovations such as next-generation stent retrievers with enhanced radial force, better clot integration, and improved navigability are further expanding their clinical utility.

In addition, new product launches are also likely to upsurge the global stent retrievers market during the forecasted period. For instance, in August 2024, Gravity Medical Technology announced the launch of its next-generation stroke treatment devices the Neutron aspiration catheter and the Supernova stent retriever. The Supernova stent retriever's innovative design enhances the capture and removal of hard fibrin-rich (white) clots, which tend to present more in non-Caucasian populations.

Therefore, owing to the above-mentioned factors, the stent retriever's category is expected to generate considerable revenue thereby pushing the overall growth of the global clot management devices market during the forecast period.

North America is expected to dominate the overall clot management devices market:

North America is expected to account for the highest proportion of the clot management devices market in 2024, out of all regions. Owing to the significance of key growth factors such as the rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension, and diabetes, the aging population, the growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth during the forecast period.

According, to recent data from the Centers for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults were diagnosed with coronary heart disease. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

The rising prevalence of coronary heart disease (CHD) significantly boosts the market for clot management devices. As CHD often leads to the formation of blood clots in coronary arteries, there is an increased demand for effective treatments to restore blood flow and prevent heart attacks. Clot management devices, such as thrombectomy and embolization systems, are essential in managing these conditions, driving their adoption in hospitals and emergency care settings.

Additionally, according to the latest report provided by the Centre for Disease Control and Prevention (2024), estimates indicated that 38.4 million people of all ages, or 11.6% of the U.S. population, had diabetes. Additionally, approximately, 38.1 million individuals aged 18 years and older, representing 14.7% of all U.S. adults, were affected by diabetes. Diabetes often leads to complications such as peripheral artery disease and deep vein thrombosis, where blood clots can block vessels and impair circulation. This rising need for effective clot prevention and treatment in diabetic populations is boosting the adoption of clot management devices, including thrombectomy and catheter systems, in both hospital and outpatient settings thereby escalating the overall market across the region.

Furthermore, one of the key reasons positively influencing the growth of the United States clot management devices market is the rising prevalence of cancers in the US population. As per the latest data provided by GLOBOCAN, in 2022, the estimated new cases of cancer in North America was 2.67 million and the projections were subjected to an increase of 3.83 million by 2045. Cancer patients are thought to have specific abnormal coagulation factors which increase the chances of thrombus formation. Additionally, chemotherapy is also related to the increased risk of venous thrombosis resulting in deep vein thrombosis. Therefore, the rising prevalence of cancers in the country is expected to aid in the growing need for thrombus management devices thereby resulting in an increase in product demand and aiding in the growth of the North America clot management devices market.

In addition, the increased strategic activities by the key market players are also likely to upsurge the clot management devices market across the region during the forecasted period. For instance, in June 2023, Penumbra, Inc., a global healthcare company, received FDA clearance and launched Lightning Bolt(TM) 7, an advanced arterial thrombectomy system. The device introduced modulated aspiration by combining Lightning Intelligent Aspiration technology with a microprocessor algorithm. It was designed to quickly remove large, fibrous arterial clots with minimal blood loss, targeting conditions like acute limb ischemia (ALI), hibernating thrombus, and visceral occlusions.

Therefore, the above-mentioned factors are expected to bolster the growth of the clot management devices market in North America during the forecast period.

Clot Management Devices Market Key Players:

Some of the key market players operating in the clot management devices market include Edward LifeSciences Corporation, Stryker, Medical Device Business Services, Inc., Medtronic PLC, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd., Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook, and others.

Recent Developmental Activities in the Clot Management Devices Market:

• In April 2024, Penumbra Inc. launched Lightning Flash 2.0 - the latest CAVT technology designed to rapidly remove blood clots
• In February 2024, CERENOVUS, Inc., part of Johnson & Johnson MedTech, announced the launch of the CEREGLIDE(TM) 71 Intermediate Catheter, designed for revascularization in acute ischemic stroke patients. This next-generation catheter, part of the CEREGLIDE family, was optimized for direct aspiration and delivering stent retrievers like the EMBOTRAP(TM) III Revascularization Device into the neurovasculature.

Key takeaways from the clot management devices market report study:

• Market size analysis for current clot management devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the clot management devices market.
• Various opportunities available for the other competitors in the clot management devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current clot management devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for clot management devices market growth in the coming future?

Target audience who can benefit from this clot management devices market report study:

• Clot management devices product providers
• Research organizations and consulting companies
• Clot management devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in clot management devices
• Various end-users who want to know more about the clot management devices market and the latest technological developments in the clot management devices market.

Frequently Asked Questions for the Clot Management Devices Market:

1. What are clot management devices?

• Clot management devices are medical devices that are employed in the removal of blood clots from peripheral as well as neurovasculature.

2. What is the market for clot management devices?

• The clot management devices market was valued at USD 1,838.79 million in 2024, growing at a CAGR of 4.63% during the forecast period from 2025 to 2032 to reach USD 2,632.73 million by 2032.

3. What are the drivers for the clot management devices market?

• The rising prevalence of cardiovascular diseases, lifestyle disorders like diabetes and hypertension, and ongoing product innovation are driving the growth of the clot management devices market. Cardiovascular conditions and related risks from these disorders increase demand for advanced clot prevention and treatment technologies. Additionally, new developments in less invasive and more effective devices, such as mechanical thrombectomy tools and catheter-based systems, are boosting market expansion, making it easier for healthcare providers to manage blood clots. Together, these factors are expected to boost the overall market for clot management devices during the forecast period from 2025 to 2032.

4. Who are the key players operating in the clot management devices market?

• Some of the key market players operating in the clot management devices market include Edward LifeSciences Corporation, Stryker, Medical Device Business Services, Inc., Medtronic PLC, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd., Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook, and others.

5. Which region has the highest share in the clot management devices market?

• North America is expected to account for the highest proportion of the clot management devices market in 2024, out of all regions. Owing to the significance of key growth factors such as the rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension, and diabetes, the aging population, the growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth during the forecast period.

Table of Contents

1. Clot Management Devices Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Clot Management Devices Market Executive Summary

• 2.1 Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1 The United States
• 4.2 Europe
• 4.3 Japan
• 4.4 China

5. Clot Management Devices Market Key Factors Analysis

• 5.1. Clot Management Devices Market Drivers
  • 5.1.1 The rising prevalence of cardiovascular diseases
  • 5.1.2 Increasing prevalence of lifestyle disorders such as diabetes and hypertension
  • 5.1.3 Increased product developmental activities across the globe.
• 5.2 Clot Management Devices Market Restraints and Challenges
  • 5.2.1 Increased number of product recalls
  • 5.2.2 The risk of complications associated with the devices
• 5.3 Clot Management Devices Market Opportunities
  • 5.3.1 Integration of artificial intelligence

6. Clot Management Devices Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Clot Management Devices Market Assessment

• 7.1 By Product Type
  • 7.1.1 Thrombectomy Devices
    • 7.1.1.1 Catheter-Directed Thrombolysis Devices
    • 7.1.1.2 Aspiration Devices
    • 7.1.1.3 Stent Retrievers
  • 7.1.2 Embelecotomy Catheters
  • 7.1.3 Inferior Vena Cava Filters
    • 7.1.3.1 Retrievable
    • 7.1.3.2 Permanent
  • 7.1.4 Compression Garments
  • 7.1.5 Others
• 7.2 By End-Users
  • 7.2.1 Hospitals
  • 7.2.2 Ambulatory Surgical Centers
  • 7.2.3 Homecare Settings
  • 7.2.4 Others
• 7.3 By Geography
  • 7.3.1 North America
    • 7.3.1.1 United States Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.1.2 Canada Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.1.3 Mexico Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.2 Europe
    • 7.3.2.1 France Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.2 Germany Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.3 United Kingdom Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.4 Italy Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.5 Spain Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.6 Rest of Europe Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.3 Asia-Pacific
    • 7.3.3.1 China Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.2 Japan Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.3 India Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.4 Australia Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.5 South Korea Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.6 Rest of Asia-Pacific Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.4 Rest of the World (RoW)
    • 7.3.4.1 Middle East Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.4.2 Africa Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.4.3 South America Clot Management Devices Market Size in USD million (2022-2032)

8. Clot Management Devices Market Company and Product Profiles

• 8.1 Edward LifeSciences Corporation
  • 8.1.1 Company Overview
  • 8.1.2 Company Snapshot
  • 8.1.3 Financial Overview
  • 8.1.4 Product Listing
  • 8.1.5 Entropy
• 8.2 Stryker
  • 8.2.1 Company Overview
  • 8.2.2 Company Snapshot
  • 8.2.3 Financial Overview
  • 8.2.4 Product Listing
  • 8.2.5 Entropy
• 8.3 Medical Device Business Services, Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Company Snapshot
  • 8.3.3 Financial Overview
  • 8.3.4 Product Listing
  • 8.3.5 Entropy
• 8.4 Medtronic PLC
  • 8.4.1 Company Overview
  • 8.4.2 Company Snapshot
  • 8.4.3 Financial Overview
  • 8.4.4 Product Listing
  • 8.4.5 Entropy
• 8.5 Penumbra
  • 8.5.1 Company Overview
  • 8.5.2 Company Snapshot
  • 8.5.3 Financial Overview
  • 8.5.4 Product Listing
  • 8.5.5 Entropy
• 8.6 Microvention Inc.
  • 8.6.1 Company Overview
  • 8.6.2 Company Snapshot
  • 8.6.3 Financial Overview
  • 8.6.4 Product Listing
  • 8.6.5 Entropy
• 8.7 Terumo Corporation
  • 8.7.1 Company Overview
  • 8.7.2 Company Snapshot
  • 8.7.3 Financial Overview
  • 8.7.4 Product Listing
  • 8.7.5 Entropy
• 8.8 Boston Scientific Inc.
  • 8.8.1 Company Overview
  • 8.8.2 Company Snapshot
  • 8.8.3 Financial Overview
  • 8.8.4 Product Listing
  • 8.8.5 Entropy
• 8.9 Abbott
  • 8.9.1 Company Overview
  • 8.9.2 Company Snapshot
  • 8.9.3 Financial Overview
  • 8.9.4 Product Listing
  • 8.9.5 Entropy
• 8.10. Acandis GmbH
  • 8.10.1 Company Overview
  • 8.10.2 Company Snapshot
  • 8.10.3 Financial Overview
  • 8.10.4 Product Listing
  • 8.10.5 Entropy
• 8.11. Perflow Medical Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Company Snapshot
  • 8.11.3 Financial Overview
  • 8.11.4 Product Listing
  • 8.11.5 Entropy
• 8.12. Koninklijke Philips N.V.
  • 8.12.1 Company Overview
  • 8.12.2 Company Snapshot
  • 8.12.3 Financial Overview
  • 8.12.4 Product Listing
  • 8.12.5 Entropy
• 8.13. phenox GmbH
  • 8.13.1 Company Overview
  • 8.13.2 Company Snapshot
  • 8.13.3 Financial Overview
  • 8.13.4 Product Listing
  • 8.13.5 Entropy
• 8.14. AngioDynamics
  • 8.14.1 Company Overview
  • 8.14.2 Company Snapshot
  • 8.14.3 Financial Overview
  • 8.14.4 Product Listing
  • 8.14.5 Entropy
• 8.15. ARGON MEDICAL
  • 8.15.1 Company Overview
  • 8.15.2 Company Snapshot
  • 8.15.3 Financial Overview
  • 8.15.4 Product Listing
  • 8.15.5 Entropy
• 8.16. BD
  • 8.16.1 Company Overview
  • 8.16.2 Company Snapshot
  • 8.16.3 Financial Overview
  • 8.16.4 Product Listing
  • 8.16.5 Entropy
• 8.17. B. Braun Melsungen AG
  • 8.17.1 Company Overview
  • 8.17.2 Company Snapshot
  • 8.17.3 Financial Overview
  • 8.17.4 Product Listing
  • 8.17.5 Entropy
• 8.18. Cardinal Health
  • 8.18.1 Company Overview
  • 8.18.2 Company Snapshot
  • 8.18.3 Financial Overview
  • 8.18.4 Product Listing
  • 8.18.5 Entropy
• 8.19. Braile Biomedica
  • 8.19.1 Company Overview
  • 8.19.2 Company Snapshot
  • 8.19.3 Financial Overview
  • 8.19.4 Product Listing
  • 8.19.5 Entropy
• 8.20. Cook
  • 8.20.1 Company Overview
  • 8.20.2 Company Snapshot
  • 8.20.3 Financial Overview
  • 8.20.4 Product Listing
  • 8.20.5 Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

• Table 1: Competitive Analysis
• Table 2: Clot Management Devices Market in Global (2022-2032)
• Table 3: Clot Management Devices Market in Global by Product Type (2022-2032)
• Table 4: Clot Management Devices Market in Global by End-User (2022-2032)
• Table 5: Clot Management Devices Market in Global by Geography (2022-2032)
• Table 6: Clot Management Devices Market in North America (2022-2032)
• Table 7: Clot Management Devices Market in the United States (2022-2032)
• Table 8: Clot Management Devices Market in Canada (2022-2032)
• Table 9: Clot Management Devices Market in Mexico (2022-2032)
• Table 10: Clot Management Devices Market in Europe (2022-2032)
• Table 11: Clot Management Devices Market in France (2022-2032)
• Table 12: Clot Management Devices Market in Germany (2022-2032)
• Table 13: Clot Management Devices Market in United Kingdom (2022-2032)
• Table 14: Clot Management Devices Market in Italy (2022-2032)
• Table 15: Clot Management Devices Market in Spain (2022-2032)
• Table 16: Clot Management Devices Market in the Rest of Europe (2022-2032)
• Table 17: Clot Management Devices Market in Asia-Pacific (2022-2032)
• Table 18: Clot Management Devices Market in China (2022-2032)
• Table 19: Clot Management Devices Market in Japan (2022-2032)
• Table 20: Clot Management Devices Market in India (2022-2032)
• Table 21: Clot Management Devices Market in Australia (2022-2032)
• Table 22: Clot Management Devices Market in South Korea (2022-2032)
• Table 23: Clot Management Devices Market in Rest of Asia-Pacific (2022-2032)
• Table 24: Clot Management Devices Market in the Rest of the World (2022-2032)
• Table 25: Clot Management Devices Market in the Middle East (2022-2032)
• Table 26: Clot Management Devices Market in Africa (2022-2032)
• Table 27: Clot Management Devices Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Clot Management Devices Market in Global (2022-2032)
• Figure 3: Clot Management Devices Market in Global by Product Type (2022-2032)
• Figure 4: Clot Management Devices Market in Global by End-User (2022-2032)
• Figure 5: Clot Management Devices Market in Global by Geography (2022-2032)
• Figure 6: Clot Management Devices Market in North America (2022-2032)
• Figure 7: Clot Management Devices Market in the United States (2022-2032)
• Figure 8: Clot Management Devices Market in Canada (2022-2032)
• Figure 9: Clot Management Devices Market in Mexico (2022-2032)
• Figure 10: Clot Management Devices Market in Europe (2022-2032)
• Figure 11: Clot Management Devices Market in France (2022-2032)
• Figure 12: Clot Management Devices Market in Germany (2022-2032)
• Figure 13: Clot Management Devices Market in United Kingdom (2022-2032)
• Figure 14: Clot Management Devices Market in Italy (2022-2032)
• Figure 15: Clot Management Devices Market in Spain (2022-2032)
• Figure 16: Clot Management Devices Market in the Rest of Europe (2022-2032)
• Figure 17: Clot Management Devices Market in Asia-Pacific (2022-2032)
• Figure 18: Clot Management Devices Market in China (2022-2032)
• Figure 19: Clot Management Devices Market in Japan (2022-2032)
• Figure 20: Clot Management Devices Market in India (2022-2032)
• Figure 21: Clot Management Devices Market in Australia (2022-2032)
• Figure 22: Clot Management Devices Market in South Korea (2022-2032)
• Figure 23: Clot Management Devices Market in Rest of Asia-Pacific (2022-2032)
• Figure 24: Clot Management Devices Market in the Rest of the World (2022-2032)
• Figure 25: Clot Management Devices Market in the Middle East (2022-2032)
• Figure 26: Clot Management Devices Market in Africa (2022-2032)
• Figure 27: Clot Management Devices Market in South America (2022-2032)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Market Opportunities
• Figure 31: PORTER'S Five Force Analysis